Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 12, 2016. The document serves as a transaction notification regarding acquisitions of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them under the Company's ShareReward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions.
| Instrument | Transaction Date | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| Ordinary Shares (25p each) | December 9, 2016 | £14.77778 | 160 shares (aggregate) | London Stock Exchange |
Note: The aggregate volume of 160 shares is derived from summing the individual transactions listed in the filing (16 or 18 shares per executive).
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It is a routine disclosure of insider share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed as part of the Company's ShareReward Plan, involving both partnership shares and matching shares.
Key Facts for Investor Verification
- Transaction Type: All reported transactions were acquisitions of ordinary shares under the ShareReward Plan, not open market sales or purchases.
- Participants: Transactions involved 11 senior executives, including CEO Sir Andrew Witty, CEO Designate Ms E Walmsley, and CFO Mr S Dingemans.
- Valuation: The share price at the time of transaction was approximately £14.78.
- Scope: This document is a regulatory notification of insider trading activity and does not reflect the company's overall financial performance for the period.